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Although there is no HbA1c threshold for cardiovascular risk, the American Diabetic Association-recommended goal of HbA1c 
< 7.0% appears to be unacceptably high. To achieve an optimal HbA1c level goal of 6.0% or less, a high dosage of sulfonylureas 
and insulin would be required; the trade-off would be the common adverse effects of hypoglycemia and weight gain. In contrast, 
hypoglycemia is uncommon with insulin sensitizers and GLP-1 analogs, allowing the physician to titrate these drugs to maxi-
mum dosage to reduce HbA1c levels below 6.0% and they have been shown to preserve β-cell function. Lastly, weight gain is 
common with sulfonylurea and insulin therapy, whereas GLP-1 analogs induce weight loss and offset the weight gain associated 
with TZDs. A treatment paradigm shift is recommended in which combination therapy is initiated with diet/exercise, metfor-
min (which has antiatherogenic effects and improves hepatic insulin sensitivity), a TZD (which improves insulin sensitivity and 
preserves β-cell function with proven durability), and a GLP-1 analog (which improves β, α-cell function and promotes weight 
loss) or a dipeptidyl peptidase IV inhibitor in patients with type 2 diabetes mellitus.
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INTRODUCTION
Beta cell failure and peripheral insulin resistance are the basic 
pathophysiologic defects of type 2 diabetes mellitus. Many stud-
ies, including the United Kingdom Prospective Diabetes Study 
(UKPDS), Steno-2, Action to Control Cardiovascular Risk in 
Diabetes (ACCORD), and Veterans Affairs Diabetes Trial 
(VADT) have demonstrated the limited efficacy of antidiabetic 
agents in terms of durability of blood glucose control and re-
duction in cardiovascular mortality. Antidiabetic agents also 
have their own treatment barriers, such as hypoglycemia and 
weight gain, which may be partly responsible for increased car-
diovascular risk, especially in the late stages of type 2 diabetes 
mellitus. 
  An early and proactive approach to treating patients with 
type 2 diabetes mellitus using a triple combination of metfor-
min, thiazolidinedione (TZD), and a glucagon-like peptide-1 
(GLP-1) analog (or dipeptidyl peptidase IV [DPP-IV] inhibi-
tor) is presented here. The goal of this treatment is to target in-
sulin resistance in the liver and muscle and islet dysfunction, 
and to cover the basic defects and shortcomings of the stepwise 
American Diabetes Association (ADA)’s theoretical treatment 
algorithm. Basic clinical investigations and studies substanti-
ating the suggestion of a paradigm shift in the treatment of type 
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2 diabetes mellitus will also be discussed briefly.
LIMITED EFFICACY OF METFORMIN AND 
SULFONYLUREA
The UKPDS clearly demonstrated that sulfonylureas had no 
protective effect on progressive β-cell failure in newly-diagnosed 
type 2 diabetic patients over the 15-year study duration [1]. 
Moreover, sulfonylureas were shown not to have a significant 
protective effect against atherosclerotic cardiovascular compli-
cations, and some studies even gave notion that sulfonylureas 
may accelerate the atherogenic process [2]. Similarly, metfor-
min-treated patients also experienced a progressive deteriora-
tion in glycemic control [3]. Although, metformin was shown 
to reduce macrovascular events in the UKPDS, evidence that 
metformin actually modifies β-cell deterioration or reduces 
cardiovascular risk is very limited. The relentless rise in hemo-
globin A1c (HbA1c) levels observed with both sulfonylureas 
and metformin resulted from a progressive decline in β-cell 
function, and by 3 years, approximately 50% of diabetic patients 
required an additional pharmacological agent to maintain 
HbA1c levels below 7.0%. Although the add-on treatment im-
proved glycemic control, after the initial decline in HbA1c con-
centrations, progressive β-cell failure continued and HbA1c 
values rose progressively. Thus, most clinical evidence shows 
that the glucose-lowering effect of sulfonylureas and metfor-
min is not durable and that the loss of glycemic control is as-
sociated with progressive β-cell failure.
  Metformin is traditionally known for its metabolic effects 
on the liver; and other metformin target tissues include skele-
tal muscle and adipose tissue. Metformin is a useful adjuvant 
to lifestyle modification in overweight and obese patients with 
type 2 diabetes mellitus, metabolic syndrome, or impaired glu-
cose tolerance (IGT). AMP-activated protein kinase (AMPK), 
a serine–threonine kinase that functions as an intracellular en-
ergy sensor, has been involved in the molecular mechanisms of 
metformin’s actions in the liver, muscle, endothelium, and the 
ovaries [4]. Although metformin failure may occur rapidly in 
clinical practice, initiating treatment soon after diabetes diag-
nosis and while HbA1c levels are low might preserve β-cell 
function, prolonging the effectiveness of metformin.
DURABILITY OF GLUCOSE CONTROL WITH 
THIAZOLIDINEDIONE
The best evidence that retardation or arrest of β-cell loss can 
be achieved comes from interventions that reduce excess body 
adiposity or change its biology. Weight loss in the Diabetes 
Prevention Program and the Finnish Diabetes Prevention Study 
was associated with ongoing reductions in the rate of type 2 
diabetes mellitus each year. This pattern would be expected if 
weight loss were slowing, or even stopping, the progression of 
β-cell deterioration. The same phenomenon has been observed 
repeatedly with TZDs, which change lipid distribution and 
adipose-tissue biology to ameliorate some adverse metabolic 
effects of obesity, including insulin resistance. 
  There are five studies in subjects with IGT demonstrating 
that TZDs prevent the progression of IGT to type 2 diabetes 
mellitus. The Diabetes Reduction Assessment with Ramipril 
and Rosiglitazone Medication study showed a 62% decrease in 
the development of type 2 diabetes mellitus with rosiglitazone, 
while the Actos Now for Prevention of Diabetes study showed 
an 81% reduction in the conversion of IGT to type 2 diabetes 
mellitus with pioglitazone. All five of these studies showed 
that, in addition to their insulin sensitizing effect, TZDs have a 
major action to preserve β-cell function. Many in vivo and in 
vitro studies with human and rodent islets have shown that 
TZDs exert a protective effect on β-cell function. Direct mea-
surement of β-cell function in the Troglitazone in Prevention 
of Diabetes and Pioglitazone in Prevention of Diabetes studies 
proved that TZDs can slow or even stop the loss of β-cell func-
tion. The mechanism appeared to be a reduction in the secre-
tory demand for insulin that occurs when insulin resistance is 
treated [5].
  In contrast to the sulfonylureas, eight long-term (> 1.5 years), 
active-comparator or double-blind placebo-controlled studies 
with TZDs present a very different picture [6-8]. After an ini-
tial decline in HbA1c levels, durability of glycemic control is 
maintained because of the preservation of β-cell function in 
type 2 diabetes mellitus patients. 
EFFICACY AND SAFETY OF GLP-1 ANALOGS
Incretins have been shown to improve β-cell function and 
maintain durability of glycemic control. In addition, the GLP-
1 analogs exenatide and liraglutide consistently lower body 
weight, and, in some studies, have favorable cardiovascular 
benefits, including lowering blood pressure, beneficial effects 
on serum lipids, and the potential to improve myocardial con-
tractility and endothelial function (effects seen with GLP-1 in-
fusions) (Table 1) [9]. Bunck et al. [10] demonstrated improved 
beta cell function in patients treated with exenatide compared 
with a glargine-treated group. First and second phase insulin 333
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secretion and C-peptide response to a hyperglycemic clamp 
were measured before and after 1 year of treatment; insulin se-
cretion increased 1.5- and 2.9-fold, respectively, and glargine 
increased the ratio of the C-peptide response during the hyper-
glycemic clamp by 31%. In contrast, exenatide increased the 
ratio more than threefold. 
  The addition of exenatide to metformin and/or sulfonylurea 
treatment for 3 years in type 2 diabetes mellitus patients result-
ed in sustained improvements in glycemic control, cardiovas-
cular risk factors, and hepatic biomarkers, coupled with pro-
gressive weight reduction. A subset of these subjects was fol-
lowed-up on for 3.5 years, and the decline in HbA1c levels was 
shown to persist [11].
  In addition to their effects on β- and α-cells, GLP-1 analogs 
reduce hepatic glucose production, appetite, and gastric motil-
ity, which are responsible for weight loss. More importantly, 
stimulation of insulin secretion and suppression of glucagon 
by exenatides is strictly dependent on plasma glucose concen-
trations, thereby minimizing the adverse effect of hypoglyce-
mia. The expectation that incretin therapy may not only im-
prove β-cell function but also increase β-cell mass in patients 
with type 2 diabetes mellitus was not substantiated, in marked 
contrast to findings in rodents [12]. 
SUGGESTIVE EXTRA-ISLET ACTION OF DPP-IV 
INHIBITORS
Although there are no studies of the long-term efficacy of DPP-
IV inhibitors on β-cell function, in short-term studies ranging 
from several months to 1 year, both sitagliptin and vildagliptin 
demonstrated a reduction in postprandial plasma glucose con-
centrations while maintaining plasma insulin response, indi-
cating a positive effect on β-cell function [13-15]. But this en-
hancement in insulin secretion does not necessarily mean pres-
ervation of β-cell function on a long-term basis. DPP-IV in-
hibitors also decrease glucagon secretion, and in concert with 
a rise in plasma insulin, lead to a reduction in basal hepatic 
glucose production [16]. Hypoglycemia does not occur with 
the DPP-IV inhibitors, but they do not suppress appetite or 
cause weight loss. 
  It is well known that GLP-1 (7-36) (and GLP-1 [7-37]) is a 
primary insulinotropic hormone on the β-cell mediated by the 
G-protein coupled receptor, GLP-1R, which activates cAMP-
dependent PKA and PI3 kinase-dependent Akt signal path-
ways. GLP-1 (9-36) amide (and GLP-1 [9-37]) is the cleavage 
product of GLP-1 (7-36) amide (and GLP-1 [7-37]) formed by 
DPP-IV within minutes. Those cleavage products (GLP-1 [7-36] 
amide) have only weak insulinotropic agonist activities on the 
GLP-1 receptor; however, they also have extra-islet actions, such 
as suppression of hepatic glucose production, antioxidant car-
dioprotection, and reduction of oxidative stress in vascular tis-
sues through binding to another receptor. Tomas and Habener 
[17] recently suggested a dual receptor hypothesis, which de-
scribes two hypothetical cell signaling pathways by which 
GLP-1 and its cleavage product exert insulinomimetic actions 
on insulin-sensitive target tissues. Prolonged inhibition of 
DPP may prevent the formation of GLP-1 (9-36) amide, and 
might ultimately augment oxidative stress in the heart, vascu-
lature, and liver, and promote hepatic glucose production, 
Table 1.  Extraglycemic effects of glucagon-like peptide-1 receptor agonists (From Mudaliar S, Henry RR. Am J Med 2010;123(3 
Suppl):S19-27, with permission from Elsevier.) [9]
Target tissue Effects Potential benefits
Pancreatic β-cell ↑ β-cell proliferation
   (seen so far only in animal/in vitro studies)
Long-term durability of glycemic effect
↓ β-cell apoptosis
   (seen so far only in animal/in vitro studies)
Potential for prevention/delay of type 2 diabetes
Cardiovascular system ↑ Myocardial contractility
   Improved endothelial funtion
↓ Cardiovascular morbidity and mortality
↓ Systolic and diastolic blood pressure
   Improved serum lipid levels
Liver ↓ Gluconeogenesis and glycogenolysis
   (seen so far only in animal/in vitro studies)
Improved hepatic sensitivity
↓ Lever fat Improved glycemic control
↓ Progression/regression of nonalcoholic fatty liver disease
Body weight ↓ Body weight Improvements in glycemia, blood pressure and serum lipids334
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which would be undesirable in the treatment of obesity-relat-
ed diabetes. Therefore, potent, short-acting DPP-IV inhibitors 
taken at meal time might provide brief stimulation of insulin 
secretion by increasing levels of insulinotropic GLP-1 (7-36) 
amide, allowing escape from DPP-IV inhibition and the inter-
mittent production of insulinomimetic GLP-1 (9-36) amide 
during interprandial periods. However, no clinical evidence 
exists demonstrating better outcomes using potent, short-act-
ing DPP-IV inhibitors instead of longer-acting DPP-IV inhibi-
tors, nor has there been a large study on the efficacy of the 
cleavage products of GLP-1 (7-36) (and GLP-1 [9-37]).
COMBINATION OF THIAZOLIDINEDIONE AND DPP-
IV INHIBITOR (Table 2)
In 175 patients (placebo group, n = 178) with type 2 diabetes 
mellitus who had not achieved adequate glycemic control with 
pioglitazone alone, 100 mg Sitagliptin was added once daily 
for 24 weeks. The addition resulted in effective glycemic con-
trol (between-treatment difference in least squares mean change 
from baseline, -0.70%) and the changes were well tolerated, 
with no increased risk of hypoglycemia compared with the 
placebo (2 vs. 0 patients, respectively) [18].
  A 24-week, multicenter, double-blind, randomized, paral-
lel-group study comparing the effects of vildagliptin (50 or 100 
mg daily) with a placebo as an add-on therapy to pioglitazone 
(45 mg daily) was conducted with 463 patients with type 2 dia-
betes mellitus that was inadequately controlled by prior TZD 
monotherapy. The patients showed an adjusted mean change 
(AMΔ) in HbA1c levels, from baseline to endpoint, of −0.8 ± 
0.1% (P = 0.001 vs. placebo) and −1.0 ± 0.1% (P < 0.001 vs. pla-
cebo), for daily dosages of 50 and 100 mg of vildagliptin, respec-
tively. Mild hypoglycemia was reported by 0, 0.6, and 1.9% of 
patients receiving vildagliptin 50 mg/day, 100 mg/day, or a pla-
cebo, respectively [19].
Table 2.  Summaries of selected clinical trials on combination of exenatide, liraglutide, sitaglipitin and vildagliptin with TZD/met-
formin (From Chia CW, Egan JM. J Clin Endocrinol Metab 2008;93:3703-16, with permission from The Endocrine Society.) [30]
Prior Rx. Weeks Trial design Intervention
No. of  
subjects
Baseline 
HbA1c
Δ HbA1c
≤ 7% 
Achieved
Δ Weight kg, 
baseline
Exenatide 
  TZD w/wo MET
16 RDPC PLB + TZD 
  w/wo MET
112 7.9 +0.1 ± 0.1 16 -0.2 ± 0.26
EXE10 μ bid
  w/wo MET
121 7.9 -0.9 ± 0.1 62 -1.75 ± 0.25
Liraglutide 
  TZD + MET
26 RDPC, parallel group PLB 177 8.4 -0.54 +0.6 ± 0.3
Lira 1.2 mg qd 178 8.5 -1.48 -1.0 ± 0.3
  Lira 1.8 mg qd 178 8.6 -1.48 -2.0 ± 0.3
Sitagliptin 
  PIO
24 RDPC, parallel group PLB + PIO 
  30-45 mg qd
173 8.0 -0.2 23 +1.5
SITA 100 mg qd 
  + PIO 30-45 qd
175 8.1 -0.9 45 +1.8
Vildagliptin 
  Drug naive
24 RDAC, prallel group PIO 45 mg qd 161 8.7 -1.4 ± 0.1 43 +1.5 ± 0.3
VILD 50 mg qd
  + PIO 15 mg qd
144 8.8 -1.7 ± 0.1 54 +1.4 ± 0.3
VILD 100 mg qd
  + PIO 30 mg qd
148 8.8 -1.9 ± 0.1 65 +2.1 ± 0.3
VILDA 100 mg qd 154 8.6 -1.1 ± 0.1 43 +0.2 ± 0.3
TZD 24 RDPC, parallel group PLB  
  + PIO 45 mg qd
158 8.7 -0.3 ± 01 15 +1.4± 0.3
VILD 50 mg qd
  + PIO 45 mg qd
147 8.6 -0.8 ± 0.1 29 0.1 ± 0.4
a
VILD 50 mg qd
  + PIO 45 mg qd
158 8.7 -1.0 ± 0.1 36 1.3 ± 0.4
a
w/wo, with/without; PLB, placebo; RDPC, randomized, double-blind, placebo-controlled; RADC, randomized double-blind, active-controlled.
aBetween-treatment difference vs. PLB group.335
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  A previous study compared the efficacy and tolerability of 
an initial combination therapy with vildagliptin/pioglitazone 
to component monotherapy [20]. The first-line treatment with 
vildagliptin/pioglitazone (both high- and low-dose regimens) 
provided better glycemic control than each component mono-
therapy with minimal hypoglycemia. The high-dose combina-
tion (100/30 mg qd) allowed 65% of patients to achieve target 
HbA1c levels (< 7%), with a tolerability profile comparable with 
pioglitazone (30 mg qd) monotherapy. The low-dose combi-
nation (50/15 mg qd) provided both efficacy and tolerability 
benefits over pioglitazone 30 mg qd. By addressing comple-
mentary mechanisms, the initial combination of vildagliptin 
and pioglitazone appears to be an effective means of achieving 
good glycemic control while attenuating drug-related adverse 
effects.
  Another study evaluated the efficacy and safety of alogliptin 
in type 2 diabetes mellitus patients with a mean duration of 7.6 
years and inadequate glycemic control using therapy with a 
thiazolidinedione and metformin/sulfonylurea. This study 
demonstrated a significant improvement in glycemic control 
after 26 weeks without clinically significant effects on the inci-
dence of hypoglycemia, which occurred most often in patients 
who also were taking a sulfonylurea [21].
  Recently, Gupta et al. [22] observed that the GIP receptor 
contains a functional PPAR-γ response element in the promot-
er region of the gene in INS-1 cells. Interventions that decreased 
or increased PPAR-γ activity (including exposure to a thiazoli-
dinedione) resulted in corresponding changes in GIP receptor 
expression in in vivo rat models. Solomon et al. [23] suggested 
improved beta cell function following lifestyle-induced weight 
loss may partly be mediated by enhanced GIP secretion and 
action in older, obese, diabetic subjects. Whether treating pa-
tients with type 2 diabetes mellitus with a thiazolidinedione 
will enhance incretin effects mediated by GIP is not known, but 
is an intriguing possibility [24]. 
TRIPLE COMBINATION - METFORMIN, 
THIAZOLIDINEDIONE AND GLP-1 ANALOGS (Table 2)
Exenatide 10 µg bid therapy for 6 weeks improved glycemic 
control (mean difference, −0.98%), reduced body weight (mean 
difference, −1.51 kg), and caused gastrointestinal symptoms 
more than placebo in 233 patients (exenatide group 121, pla-
cebo group 112) with type 2 diabetes mellitus that was subop-
timally controlled with TZD ± metformin [25]. 
  A triple combination therapy of liraglutide, metformin, and 
TZD for 26 weeks in 533 subjects (1:1:1) randomized to once-
daily liraglutide (1.2 or 1.8 mg) or liraglutide placebo in com-
bination with metformin (1 g twice daily) and rosiglitazone (4 
mg twice daily) demonstrated significantly greater mean 
ΔHbA1c values in the liraglutide groups versus placebo (mean 
± SE, −1.5 ± 0.1% for both 1.2 and 1.8 mg liraglutide and −0.5 
± 0.1% for placebo). Minor hypoglycemia occurred more fre-
quently with liraglutide, but there was no major hypoglycemia. 
Gastrointestinal adverse events were more common with lira-
glutide, but most occurred early in the study period and were 
transient. Investigators concluded that the triple combination 
of liraglutide, metformin, and TZD is an effective and safe 
treatment for patients with type 2 diabetes mellitus [26]. In a 
14-week extension study of Liraglutide Effect and Action in 
Diabetes 6 trial, patients switched from 10 μg twice-daily ex-
enatide to 1.8 mg liraglutide once-daily or 40 weeks of contin-
ued liraglutide. Liraglutide improved HbA1c levels (Δ 0.32%), 
fasting plasma glucose, and homeostasis model of β-cell func-
tion values more so than exenatide, with less persistent nausea 
and hypoglycemia. Over 40 weeks, liraglutide reduced HbA1c 
levels by 1.3% [27].
  A 20-week study to observe the effects of exenatide plus rosi-
glitazone on β-cell function and insulin sensitivity using hyper-
glycemic and euglycemic insulin clamp techniques in type 2 
diabetes mellitus patients currently taking metformin has been 
conducted [28]. Exenatide and rosiglitazone significantly im-
proved the M value at 20 weeks (P < 0.05), while exenatide had 
no significant effect on insulin-stimulated glucose disposal. 
After 80 to 90 minutes of the hyperglycemic clamp the dispo-
sition index increased significantly and similarly with exenatide 
and rosiglitazone (both P < 0.001) but not with rosiglitazone 
[28]. These results demonstrate that exenatide has a positive 
influence on β-cell function but does not exert any significant 
insulin–sensitizing action, as determined by the M value dur-
ing the insulin clamp. Rosiglitazone, however, caused a two-fold 
increase in insulin sensitivity, measured as M/I during the eu-
glycemic insulin clamp. Conclusively, therapy with exenatide 
and rosiglitazone, in addition to metformin, offset the weight 
gain observed with rosiglitazone and elicited an additive effect 
on glycemic control with significant improvements in β-cell 
function and insulin sensitivity. 
CONCLUSION
The stepped ADA algorithm of metformin/sulfonylurea thera-336
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py in type 2 diabetes mellitus has been proven ineffective in 
achieving durable glycemic control even in newly-diagnosed 
patients. However, TZDs and GLP-1 analogs, when used as 
monotherapy, have been shown to have a more durable effect. 
When used in combination, one would expect an even more 
durable effect on preservation of β-cell function and reduction 
in HbA1c levels, although this remains to be proven in a lon-
ger-term study. In contrast to sulfonylurea and metformin, 
both TZDs and GLP-1 analogs have been shown to preserve 
β-cell function. Although there is no HbA1c threshold for car-
diovascular risk, the ADA-recommended goal of HbA1c < 
7.0% appears to be unacceptably high. To achieve an optimal 
HbA1c level goal of 6.0% or less, a high dosage of sulfonyl-
ureas and insulin would be required; the trade-off would be 
the common adverse effects of hypoglycemia and weight gain. 
In contrast, hypoglycemia is uncommon with insulin sensitiz-
ers and GLP-1 analogs, allowing the physician to titrate these 
drugs to maximum dosage to reduce HbA1c levels below 
6.0%. Lastly, weight gain is common with sulfonylurea and in-
sulin therapy, whereas GLP-1 analogs induce weight loss and 
offset the weight gain associated with TZDs. 
  A treatment paradigm shift is recommended in which com-
bination therapy is initiated with diet/exercise, metformin 
(which has antiatherogenic effects and improves hepatic insu-
lin sensitivity), a TZD (which improves insulin sensitivity and 
preserves β-cell function with proven durability), and a GLP-1 
analog (which improves β, α-cell function and promotes weight 
loss) or a DPP-IV inhibitor (Fig. 1) [29,30].
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